What are the causes of isolated thrombocytosis in a 64‑year‑old man with a platelet count of 478 ×10⁹/L and otherwise normal complete blood count?

Causes of Isolated Thrombocytosis in a 64-Year-Old Male

In a 64-year-old man with a platelet count of 478 × 10⁹/L and otherwise normal blood counts, the most likely causes are reactive (secondary) thrombocytosis from conditions such as infection, tissue injury, chronic inflammation, iron deficiency, or occult malignancy, though primary thrombocytosis from essential thrombocythemia must also be considered.

Primary vs. Secondary Thrombocytosis

The differential diagnosis fundamentally divides into two categories:

Secondary (Reactive) Thrombocytosis - Most Common

Secondary thrombocytosis accounts for approximately 83-88% of all thrombocytosis cases 1, 2. The major causes include:

• Tissue injury/damage (32-42% of secondary cases) - recent surgery, trauma, burns 1, 2
• Infection (17-24% of secondary cases) - bacterial, viral, or fungal infections 1, 3, 2
• Chronic inflammatory disorders (10-13% of secondary cases) - inflammatory bowel disease, rheumatoid arthritis, vasculitis 1, 2
• Iron deficiency anemia (11% of secondary cases) - even with normal hemoglobin, check ferritin and iron studies 4, 1
• Malignancy (13% of secondary cases) - solid tumors, lymphoproliferative disorders 4, 2
• Prior splenectomy - loss of splenic platelet sequestration 4

Clinical context matters: In secondary thrombocytosis, look for fever, tachycardia, weight loss, hypoalbuminemia, neutrophilia, leukocytosis, or anemia as associated findings 3. Patients with comorbidities including diabetes, dementia, indwelling prostheses, or paraplegia/quadriplegia have higher likelihood of infectious causes 3.

Primary Thrombocytosis - Less Common but Critical to Identify

Primary thrombocytosis accounts for 12-12.5% of cases 1, 2. Essential thrombocythemia (ET) is the most common primary cause (45-86% of primary cases) 1, 2.

WHO diagnostic criteria for ET require ALL four of the following 4:

1. Sustained platelet count ≥ 450 × 10⁹/L (this patient meets this criterion)
2. Bone marrow biopsy showing megakaryocytic proliferation with enlarged, mature megakaryocytes; no significant increase in granulopoiesis or erythropoiesis
3. Exclusion of other myeloid neoplasms: polycythemia vera, primary myelofibrosis, chronic myeloid leukemia, myelodysplastic syndromes
4. Demonstration of JAK2V617F or other clonal marker (CALR, MPL), OR in absence of clonal marker, no evidence for reactive thrombocytosis

Approximately 80% of ET patients harbor driver mutations: JAK2V617F, CALR, or MPL in mutually exclusive fashion 5. An additional 50% have other mutations including TET2, ASXL1, DNMT3A, or SF3B1 5.

Key Distinguishing Features

Primary thrombocytosis is associated with 1, 2:

• Higher platelet counts (median significantly higher than secondary)
• Extreme thrombocytosis (≥ 800 × 10⁹/L) more common
• Prolonged duration (> 1 month persistence)
• Increased thrombotic risk - both arterial and venous thrombosis
• Increased hemorrhagic risk with extreme thrombocytosis (≥ 1,500 × 10⁹/L) due to acquired von Willebrand disease 6

Secondary thrombocytosis characteristics 2:

• Venous thrombosis only occurs when additional risk factors present
• More rapid normalization of platelet count once underlying cause treated 3
• Higher mortality risk related to underlying condition rather than thrombocytosis itself 3

Recommended Diagnostic Approach

For this 64-year-old man with platelet count 478 × 10⁹/L:

1. Assess for secondary causes first 4:

   • Complete history: recent surgery, trauma, infections, inflammatory conditions, cancer history, splenectomy
   • Iron studies: serum ferritin, iron, TIBC (iron deficiency can cause thrombocytosis even with normal hemoglobin) 4
   • Inflammatory markers: ESR, CRP, fibrinogen 2
   • Screen for occult infection or malignancy based on clinical suspicion 3

2. If no clear secondary cause identified, evaluate for primary thrombocytosis 4, 5:

   • JAK2V617F mutation testing - present in ~60% of ET patients 5
   • CALR and MPL mutation testing if JAK2 negative 5
   • Bone marrow biopsy with morphology and cytogenetics - essential to confirm ET diagnosis and exclude prefibrotic myelofibrosis, polycythemia vera, or myelodysplastic syndromes 4
   • BCR-ABL testing to exclude chronic myeloid leukemia 4

3. Repeat platelet count to confirm sustained elevation (not transient reactive process) 4

Critical Pitfalls to Avoid

• Do not assume thrombocytosis is benign without investigation - primary thrombocytosis carries significant thrombotic risk requiring intervention 1, 2
• Do not overlook iron deficiency - check iron studies even with normal hemoglobin and MCV 4
• Do not diagnose ET without bone marrow biopsy - morphology is essential to exclude prefibrotic myelofibrosis, which has different prognosis and management 4
• In iron-deficient patients, trial iron replacement before excluding polycythemia vera, as occult PV may be masked 4
• Consider concomitant conditions - a patient can have both reactive thrombocytosis AND essential thrombocythemia if first three WHO criteria are met 4

Prognostic Implications

If primary thrombocytosis (ET): Median survival approaches 18 years overall, exceeding 35 years in younger patients 5. Life expectancy is reduced compared to general population 5. Risk stratification guides therapy - this 64-year-old patient would be intermediate or high risk depending on JAK2 mutation status and thrombosis history 5.

If secondary thrombocytosis: Prognosis depends entirely on underlying condition 3, 2. Thrombocytosis itself does not increase thrombotic risk unless additional risk factors present 2.